全文获取类型
收费全文 | 133975篇 |
免费 | 10721篇 |
国内免费 | 5492篇 |
专业分类
耳鼻咽喉 | 984篇 |
儿科学 | 2383篇 |
妇产科学 | 1423篇 |
基础医学 | 23603篇 |
口腔科学 | 2544篇 |
临床医学 | 10134篇 |
内科学 | 22104篇 |
皮肤病学 | 2234篇 |
神经病学 | 11556篇 |
特种医学 | 2190篇 |
外国民族医学 | 29篇 |
外科学 | 9000篇 |
综合类 | 19989篇 |
现状与发展 | 31篇 |
预防医学 | 6697篇 |
眼科学 | 1564篇 |
药学 | 19152篇 |
11篇 | |
中国医学 | 4780篇 |
肿瘤学 | 9780篇 |
出版年
2024年 | 199篇 |
2023年 | 1803篇 |
2022年 | 2814篇 |
2021年 | 5191篇 |
2020年 | 4147篇 |
2019年 | 4170篇 |
2018年 | 4230篇 |
2017年 | 4483篇 |
2016年 | 4513篇 |
2015年 | 5177篇 |
2014年 | 8069篇 |
2013年 | 9323篇 |
2012年 | 8471篇 |
2011年 | 9699篇 |
2010年 | 7667篇 |
2009年 | 7532篇 |
2008年 | 7429篇 |
2007年 | 7034篇 |
2006年 | 6327篇 |
2005年 | 5664篇 |
2004年 | 4867篇 |
2003年 | 4107篇 |
2002年 | 3143篇 |
2001年 | 2606篇 |
2000年 | 2359篇 |
1999年 | 1998篇 |
1998年 | 1891篇 |
1997年 | 1714篇 |
1996年 | 1456篇 |
1995年 | 1296篇 |
1994年 | 1171篇 |
1993年 | 990篇 |
1992年 | 837篇 |
1991年 | 791篇 |
1990年 | 677篇 |
1989年 | 550篇 |
1988年 | 478篇 |
1987年 | 470篇 |
1986年 | 444篇 |
1985年 | 702篇 |
1984年 | 720篇 |
1983年 | 457篇 |
1982年 | 525篇 |
1981年 | 415篇 |
1980年 | 362篇 |
1979年 | 265篇 |
1978年 | 204篇 |
1977年 | 188篇 |
1976年 | 193篇 |
1975年 | 138篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
目的:探讨血清糖类抗原125(carbohydrate antigen 125,CA125)、人附睾蛋白4(human epididymis protein 4,HE4)、中性粒细胞与淋巴细胞比值(neutrophil-lymphocyte ratio,NLR)联合检测在子宫内膜癌诊断中的作用。方法:选取42例子宫内膜癌患者、50例子宫内膜良性疾病患者和50例健康体检人群。采用SYSMEX XN550全自动血液分析仪计数术前外周血中性粒细胞和淋巴细胞,计算NLR;采用Maglumi4000全自动化学发光仪检测术前血清CA125、HE4水平。采用ROC曲线分析CA125、HE4、NLR和三者联合指标在诊断子宫内膜癌中的作用。结果:外周血NLR在健康组、良性组和子宫内膜癌组中逐渐增高,且差异有统计学意义(P<0.05);子宫内膜癌组HE4表达量显著高于良性组与健康组(P<0.05),而良性组与健康组之间差异无统计学意义(P>0.05);CA125表达量在三组中差异无统计学意义(P>0.05)。CA125、HE4、NLR及三者联合标记物的AUC分别为0.530、0.733、0.795、0.823,当分别取它们的临界值时,特异性分别为70.8%、85.1%、61.7%、83.0%,敏感性分别为40.0%、63.3%、86.7%、73.3%。单项指标NLR的敏感性最高,HE4的特异性最高,联合指标的特异性和敏感性都很高。结论:术前血清CA125、HE4和NLR联合检测具有较高的特异性和敏感性,联合检测可以互为补充,提高子宫内膜癌的诊断准确率,对子宫内膜癌的诊断具有指导意义。 相似文献
44.
A growing body of data suggests that therapies based on Toll-like receptors (TLR) targeting, in particular TLR4, holds promise in curing autoimmune and inflammatory pathologies still lacking specific treatment, included several rare diseases. While TLR4 activators (agonists) have already found successful clinical application as vaccine adjuvants, the use of TLR4 blockers (antagonists) as antisepsis agents or as agents against inflammatory diseases (including arthritis, multiple sclerosis, neuroinflammations) and cancer is still at a preclinical phase of development. This minireview focuses on recent achievements on the development of TLR4 modulators based on lipid A structure simplification, in particular on compounds having disaccharide or monosaccharide structures. As the TLR4 activity of natural TLR4 ligands (lipopolysaccharide, LPS and its biologically active part, the lipid A) depends on both the structure of endotoxin aggregates in solution and on single-molecule interaction with MD-2 and CD14 receptors, the rational design of TLR4 modulators should in principle take into account both these factors. In the light of the most recent advances in the field, in this minireview we discuss the structure–activity relationship in simplified lipid A analogs, with cationic or anionic amphiphilic structures. 相似文献
45.
背景与目的:在前列腺癌标准化疗方案中,多西他赛(docetaxel,DTX)引起的化疗耐药是引起患者死亡的重要原因之一,然而DTX引起的化疗耐药相关机制尚未知。探讨前列腺癌DTX耐药的作用机制。方法:收集2016年6月—2019年6月在武汉市第三医院进行化疗的40例患者,包括20例DTX耐药和20例DTX敏感患者。人前列腺癌细胞系PC-3在一系列逐渐增加的DTX浓度梯度处理下形成耐药株PC-3/DTX。采用实时荧光定量聚合酶链反应(real-time fluorescence quantitative polymerase chain reaction,RTFQ-PCR)检测miR-503和TLR4 mRNA的表达,采用蛋白质印迹法(Western blot)检测TLR4蛋白的水平,采用双荧光素酶报告基因检测miR-503和TLR4的相互作用,采用四甲基偶氮唑蓝(methyl thiazolyl tetrazolium,MTT)法检测细胞活力,采用流式细胞术检测细胞凋亡。结果:前列腺癌耐药患者组织和耐药细胞系中miR-503的表达较敏感组显著降低(P=0.013),而TLR4显著增加(P=0.005 6)。过表达miR-503显著抑制耐药细胞的增殖,促进凋亡,同时抑制耐药相关蛋白MDR-1的表达,而过表达TLR4则促进细胞的增殖,抑制凋亡,促进耐药相关蛋白MDR-1的表达。结论:miR-503通过靶向调控TLR4的表达影响前列腺癌的DTX耐药。 相似文献
46.
47.
Xue Wen Ping An Hexuan Li Zijian Zhou Yimin Sun Jian Wang Lixiang Ma Boxun Lu 《神经科学通报》2020,36(12):1414
Expansions of trinucleotide or hexanucleotide repeats lead to several neurodegenerative disorders, including Huntington disease [caused by expanded CAG repeats (CAGr) in the HTT gene], and amyotrophic lateral sclerosis [ALS, possibly caused by expanded GGGGCC repeats (G4C2r) in the C9ORF72 gene], of which the molecular mechanisms remain unclear. Here, we demonstrated that lowering the Drosophila homologue of tau protein (dtau) significantly rescued in vivo neurodegeneration, motor performance impairments, and the shortened life-span in Drosophila expressing expanded CAGr or expanded G4C2r. Expression of human tau (htau4R) restored the disease-related phenotypes that had been mitigated by the loss of dtau, suggesting an evolutionarily-conserved role of tau in neurodegeneration. We further revealed that G4C2r expression increased tau accumulation by inhibiting autophagosome–lysosome fusion, possibly due to lowering the level of BAG3, a regulator of autophagy and tau. Taken together, our results reveal a novel mechanism by which expanded G4C2r causes neurodegeneration via an evolutionarily-conserved mechanism. Our findings provide novel autophagy-related mechanistic insights into C9ORF72-ALS and possible entry points to disease treatment.Electronic supplementary materialThe online version of this article (10.1007/s12264-020-00518-2) contains supplementary material, which is available to authorized users. 相似文献
48.
49.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献